↓ Skip to main content

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter
18 X users

Citations

dimensions_citation
44 Dimensions

Readers on

mendeley
59 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Published in
Journal for Immunotherapy of Cancer, December 2018
DOI 10.1186/s40425-018-0427-6
Pubmed ID
Authors

Yaxiong Zhang, Huaqiang Zhou, Li Zhang

X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 59 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 17%
Student > Bachelor 6 10%
Student > Doctoral Student 5 8%
Other 5 8%
Researcher 5 8%
Other 8 14%
Unknown 20 34%
Readers by discipline Count As %
Medicine and Dentistry 19 32%
Pharmacology, Toxicology and Pharmaceutical Science 9 15%
Nursing and Health Professions 3 5%
Agricultural and Biological Sciences 2 3%
Sports and Recreations 1 2%
Other 1 2%
Unknown 24 41%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 July 2020.
All research outputs
#3,250,160
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#890
of 3,424 outputs
Outputs of similar age
#69,907
of 445,099 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#30
of 63 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,099 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.